Floatz logo

Rovalpituzumab Tesirine

Large-Cell Neuroendocrine Carcinoma

AbbVieantibody_drug_conjugatePhase 1/2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Large-Cell Neuroendocrine Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Bms-907351
National Cancer Institute (NCI)
Phase 2CCC
DEXAMETHASONE
AbbVie
Phase 1/2CCC
[203Pb]Pb-MP0712
Molecular Partners AG
Phase 1/2CCC

View all 11 →

Same molecule, other indications

Rovalpituzumab Tesirine is also rated in:

small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
medullary thyroid gland carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
prostate neuroendocrine neoplasmDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →